Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CARsgen Therapeutics HoldingsCRTHF 21 PS Ratio is 59.53 as of Jul. 14, 2026, which is 56% below its 10-year median of 134.94. GuruFocus rates CRTHF with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, CARsgen Therapeutics Holdings ranks worse than 80.97% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CARsgen Therapeutics Holdings's share price is $1.905.
CARsgen Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03. Hence, CARsgen Therapeutics Holdings's PS Ratio for today is 59.53.
The historical rank and industry rank for CARsgen Therapeutics Holdings's PS Ratio or its related term are showing as below:
CRTHF'
s PS Ratio Range Over the Past 10 Years
Min: 32.68 Med: 134.94 Max: 335.37
Current: 62
During the past 7 years, CARsgen Therapeutics Holdings's highest PS Ratio was 335.37. The lowest was 32.68. And the median was 134.94.
CRTHF's PS Ratio is ranked worse than 80.97% of 930
companies
in the Biotechnology industry
Industry Median: 9.405
vs CRTHF: 62.00
During the past 7 years, CARsgen Therapeutics Holdings's highest 3-Year average Revenue per Share Growth Rate was -2.50% per year. The lowest was -2.50% per year. And the median was -2.50% per year.
Back to Basics: PS Ratio
CARsgen Therapeutics Holdings (OTCPK:CRTHF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
CARsgen Therapeutics Holdings PS Ratio Related Terms
CARsgen Therapeutics Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CARsgen Therapeutics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARsgen Therapeutics Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where CARsgen Therapeutics Holdings's PS Ratio falls into.
CARsgen Therapeutics Holdings PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CARsgen Therapeutics Holdings's Share Price of today is $1.905.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CARsgen Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CARsgen Therapeutics Holdings (CRTHF) has a PS Ratio of 59.53 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CARsgen Therapeutics Holdings and its competitors. This is 56% below median its historical median of 134.94. Over the past decade, CARsgen Therapeutics Holdings' PS Ratio has ranged from 32.68 to 335.37. According to the industry distribution chart, CARsgen Therapeutics Holdings ranks #753 out of 930 companies in the Biotechnology industry, placing it in the top 81%.
Is CARsgen Therapeutics Holdings' PS Ratio too high?
CARsgen Therapeutics Holdings' current PS Ratio of 59.53 is 56% below median its 10-year median of 134.94. Over the past 10 years, this metric has ranged from a low of 32.68 to a high of 335.37. The Biotechnology industry median PS Ratio is 9.41. CARsgen Therapeutics Holdings' value of 59.53 is 533% above this industry median. Based on the distribution chart, CARsgen Therapeutics Holdings ranks #753 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARsgen Therapeutics Holdings ranks #753 out of 930 companies for PS Ratio. This places CARsgen Therapeutics Holdings in the lower half of its industry. The industry median PS Ratio is 9.41. CARsgen Therapeutics Holdings' value of 59.53 is 533% above this benchmark. Historically, CARsgen Therapeutics Holdings' own PS Ratio has ranged from 32.68 to 335.37 over the past decade. While the company's 10-year median is 134.94 vs. the industry median of 9.41, CARsgen Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CARsgen Therapeutics Holdings's current PS Ratio of 59.53 is 533% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CARsgen Therapeutics Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARsgen Therapeutics Holdings's current PS Ratio is 59.53, which is 56% below median its own 10-year median of 134.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (CRTHF) has a current PS Ratio of 59.53. The current PS Ratio is 59.53, which is 56% below median its 10-year median of 134.94 and 533% above the Biotechnology industry median of 9.41. CARsgen Therapeutics Holdings' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (CRTHF), the current PS Ratio is 59.53 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CARsgen Therapeutics Holdings Business Description
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
21GF Score
Get the complete analysis for CRTHF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRTHF has been successfully added to your 
